Krystal Biotech, Inc. KRYS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $116.36M+8.6% | $107.11M+9.5% | $97.8M+1.8% | $96.04M+8.9% | $88.18M-3.2% | ||
| $15.33M+3.6% | $14.79M+1.4% | $14.59M+1.2% | $14.41M+1.1% | $14.26M+5.4% | ||
| $41.01M-1.0% | $41.45M+10.3% | $37.58M+6.9% | $35.16M+7.7% | $32.65M+4.3% | ||
| $62.67M-0.3% | $62.84M+11.4% | $56.43M-0.5% | $56.74M+9.3% | $51.93M+4.4% | ||
| $62.67M-0.3% | $62.84M+11.4% | $56.43M-0.5% | $56.74M+9.3% | $51.93M+4.4% | ||
| $53.69M+21.3% | $44.27M+7.0% | $41.37M+5.3% | $39.31M+8.4% | $36.25M-12.4% | ||
| 46.1%+4.8pp | 41.3%-1.0pp | 42.3%+1.4pp | 40.9%-0.2pp | 41.1%-4.3pp | ||
| $7.75M+13.0% | $6.86M+4.1% | $6.59M-11.7% | $7.47M+1.7% | $7.35M+1.5% | ||
| $61.44M+20.2% | $51.13M+6.6% | $47.97M+2.5% | $46.78M+7.3% | $43.6M-10.3% | ||
| $5.51M+2,148% | -$269K+99.1% | -$31.4M-472% | $8.44M+7.3% | $7.86M+151% | ||
| $55.93M+8.8% | $51.4M-35.2% | $79.37M+107% | $38.33M+7.3% | $35.73M-21.4% | ||
| 48.1%+0.1pp | 48%-33.2pp | 81.2%+41.2pp | 39.9%-0.6pp | 40.5%-9.4pp | ||
| $1.83+7.6% | $1.70-36.1% | $2.66+106% | $1.29+7.5% | $1.20-21.6% | ||
| $1.91+7.9% | $1.77-35.4% | $2.74+106% | $1.33+7.3% | $1.24-22.0% | ||
| 30.5M+1.9% | 30M+0.4% | 29.8M+0.3% | 29.7M-0.4% | 29.9M+0.4% | ||
| 29.3M+1.2% | 28.9M0.0% | 29M+0.1% | 28.9M+0.3% | 28.8M+0.8% | ||
| $6.32M-4.1% | $6.59M+54.6% | $4.26M-40.5% | $7.17M+42.5% | $5.03M+1.6% | ||
| —— | $0— | $0— | $0— | $0+100% | ||
| $7.75M+13.0% | $6.86M+4.1% | $6.59M-11.7% | $7.47M+1.7% | $7.35M+1.5% | ||
| $53.17M+3.4% | $51.44M-35.1% | $79.31M+103% | $39.1M+7.7% | $36.31M-17.1% | ||
| $1.52M-2.6% | $1.56M+11.6% | $1.4M+7.7% | $1.3M-7.8% | $1.41M+3.4% | ||
| -$1.58M— | —— | $657K+516% | -$158K-146% | $344K+130% | ||
| $116.36M+8.6% | $107.11M+9.5% | $97.8M+1.8% | $96.04M+8.9% | $88.18M-3.2% | ||
| $53.69M+21.3% | $44.27M+7.0% | $41.37M+5.3% | $39.31M+8.4% | $36.25M-12.4% | ||
| $55.21M+20.5% | $45.83M+7.1% | $42.77M+5.3% | $40.61M+7.8% | $37.66M-11.9% | ||
| $55.21M+20.5% | $45.83M+7.1% | $42.77M+5.3% | $40.61M+7.8% | $37.66M-11.9% | ||
| 47.4%+4.7pp | 42.8%-0.9pp | 43.7%+1.5pp | 42.3%-0.4pp | 42.7%-4.2pp | ||
| $53.69M+21.3% | $44.27M+7.0% | $41.37M+5.3% | $39.31M+8.4% | $36.25M-12.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Krystal Biotech, Inc.'s revenue?
- Krystal Biotech, Inc. (KRYS) generated $417.3M in revenue over the trailing twelve months, up 25.1% year over year.
- Is Krystal Biotech, Inc. profitable?
- Krystal Biotech, Inc. reported $225.0M in net income over the trailing twelve months, a 53.9% net margin.
- What is Krystal Biotech, Inc.'s earnings per share?
- Krystal Biotech, Inc.'s diluted EPS over the trailing twelve months is $7.48.
- Where does Krystal Biotech, Inc.'s income statement data come from?
- Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
